© 2024 Myocardial Solutions Inc. All rights reserved.
MORRISVILLE, N.C., February 7, 2019 – The Journal of Medical Economics published a manuscript authored by Avalon Health Economics (Avalon) that demonstrates the significant cost savings that could be achieved by using MyoStrain® to diagnose coronary artery disease (CAD). The article compares MyoStrain to the current standard of care, single-photon emission computed tomography (SPECT) stress testing. Avalon developed a cost impact model from both a ‘payer perspective’ and a ‘hospital perspective’ to compare MyoStrain stress test versus SPECT stress test.
The link to the manuscript is provided below:
Citation: Ivana Stojanovic, John E. Schneider & Jacie Cooper (2019). Cost-impact of cardiac magnetic resonance imaging with Fast-SENC compared to SPECT in the diagnosis of coronary artery disease in the U.S., Journal of Medical Economics, DOI: 10.1080/13696998.2019.1580713
PR@myocardialsolutions.com
919.677.8100
Myocardial Solutions, Inc. (MSI) is a medical technology company working to transform the cardiac and cancer care continuum. Leveraging more than 400 publications in clinical research and development, MSI’s proprietary technology, MyoStrain®, is a 10-minute, MRI-based heart function test providing physicians with sensitive diagnostic markers to support the early assessment and individualized treatment of heart dysfunction. MyoStrain has received FDA-510(k) pre-market clearance, CE-mark certification, and is commercially available in the United States and Europe.
To learn more about MyoStrain, visit myocardialsolutions.com or connect with us on LinkedIn and Twitter @myocardialsoln.
808 Aviation Pkwy, Suite 700 | Morrisville, NC 27560 | myocardialsolutions.com | ph: +1.919.677.8100
© Copyright 2022 Myocardial Solutions Inc. All rights reserved. MyoStrain® and the MyoHealthTM
Score are among the trademarks of Myocardial Solutions.
